Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA and virtually, May 16-20, 2023. Additionally, the Company will present a trials-in-progress poster from its phase 2 clinical trial of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) 27th Annual Meeting in Chicago, IL and virtually, June 2-6, 2023.
Details are as follows:
ASGCT 26th Annual Meeting
- Oral Presentation Title: Safety and Survival Outcomes in Recurrent High-Grade Glioma Patients Treated with CAN-3110, a First-in-Class ICP34.5 Expressing Oncolytic HSV1
- Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
- Session Title: Late-Breaking Abstracts 1
- Session Date/Time: Friday, May 19, 2023, 8:00 am - 9:45 am PT
- Location: Room 515 AB, Los Angeles Convention Center, Los Angeles, CA
ASCO 27th Annual Meeting
- Trials-in-Progress Poster Presentation Title: CAN-2409 Plus Prodrug with Standard of Care Immune Checkpoint Inhibitor for Patients with Stage III/IV NSCLC
- Presenter: Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
- Session Title: Poster Session – Lung Cancer – Non-Small Cell Metastatic
- Session Date/Time: Sunday, June 4, 2023, 8:00 am - 11:00 am CT
- Location: Hall A, McCormick Place Convention Center, Chicago, IL
Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies that elicit a systemic anti-tumor immune response to help patients fight cancer. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform; it’s an off-the-shelf therapy, producing an individualized cancer response. CAN-3110 is the lead product candidate from the HSV platform. Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit www.candeltx.com.
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s most recent Annual Report on Form 10-K filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Wheelhouse Life Science Advisors
Wheelhouse Life Science Advisors